"Pyridines" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Compounds with a six membered aromatic ring containing NITROGEN. The saturated version is PIPERIDINES.
Descriptor ID |
D011725
|
MeSH Number(s) |
D03.383.725
|
Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Pyridines".
Below are MeSH descriptors whose meaning is more specific than "Pyridines".
This graph shows the total number of publications written about "Pyridines" by people in this website by year, and whether "Pyridines" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
1994 | 1 | 2 | 3 |
1995 | 1 | 2 | 3 |
1996 | 1 | 0 | 1 |
1997 | 1 | 0 | 1 |
1998 | 1 | 2 | 3 |
1999 | 1 | 1 | 2 |
2000 | 4 | 1 | 5 |
2001 | 2 | 5 | 7 |
2002 | 2 | 0 | 2 |
2003 | 0 | 3 | 3 |
2004 | 1 | 4 | 5 |
2005 | 1 | 7 | 8 |
2006 | 4 | 1 | 5 |
2007 | 5 | 4 | 9 |
2008 | 5 | 2 | 7 |
2009 | 9 | 4 | 13 |
2010 | 14 | 5 | 19 |
2011 | 11 | 2 | 13 |
2012 | 6 | 5 | 11 |
2013 | 5 | 4 | 9 |
2014 | 6 | 3 | 9 |
2015 | 7 | 2 | 9 |
2016 | 8 | 5 | 13 |
2017 | 4 | 5 | 9 |
2018 | 6 | 6 | 12 |
2019 | 1 | 6 | 7 |
2020 | 4 | 5 | 9 |
2021 | 6 | 7 | 13 |
2022 | 0 | 6 | 6 |
2023 | 2 | 0 | 2 |
2024 | 2 | 2 | 4 |
To return to the timeline,
click here.
Below are the most recent publications written about "Pyridines" by people in Profiles.
-
Palbociclib in Patients With Soft Tissue Sarcoma With CDK4 Amplifications: Results From the Targeted Agent and Profiling Utilization Registry Study. JCO Precis Oncol. 2024 Jul; 8:e2400219.
-
Lasofoxifene as a potential treatment for aromatase inhibitor-resistant ER-positive breast cancer. Breast Cancer Res. 2024 Jun 07; 26(1):95.
-
Regorafenib in Patients With Solid Tumors With BRAF Alterations: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) Study. JCO Precis Oncol. 2024 Apr; 8:e2300527.
-
Sotorasib with panitumumab in chemotherapy-refractory KRASG12C-mutated colorectal cancer: a phase 1b trial. Nat Med. 2024 Jan; 30(1):265-270.
-
A simplified protocol for the automated production of 2-[18 F]fluoro-3-[2-((S)-3-pyrrolinyl)methoxy]pyridine ([18 F]nifene) on an IBA Synthera® module. J Labelled Comp Radiopharm. 2024 Jan; 67(1):31-36.
-
Development of Masitinib Derivatives with Enhanced Mpro Ligand Efficiency and Reduced Cytotoxicity. Molecules. 2023 Sep 15; 28(18).
-
Serine biosynthesis as a novel therapeutic target for dilated cardiomyopathy. Eur Heart J. 2022 09 21; 43(36):3477-3489.
-
Overcoming Taxane Resistance: Preclinical and Phase 1 Studies of Relacorilant, a Selective Glucocorticoid Receptor Modulator, with Nab-Paclitaxel in Solid Tumors. Clin Cancer Res. 2022 08 02; 28(15):3214-3224.
-
Selpercatinib-Induced Hypothyroidism Through Off-Target Inhibition of Type 2 Iodothyronine Deiodinase. JCO Precis Oncol. 2022 06; 6:e2100496.
-
Pfizer and Palbociclib in China: Analyzing an Oncology Pay-for-Performance Plan. Value Health Reg Issues. 2022 Sep; 31:34-38.